Alliance Pharma Regulatory News (APH)

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Director's Dealings

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, announces that the Company was notified on 25 October 2012 that the interests of Mr Anthony Booley, a Director of the Company, in the ordinary shares of the Company ("Shares") have changed as follows. On 25 October 2012 Mr Booley transferred 1,166,667 Shares to the Booley Family Trust, in which he has a beneficial interest, and 4,224,056 Shares to his wife, Mrs Lynette Booley. Mrs Booley subsequently sold 800,000 Shares at 30.5p and transferred 1,166,667 Shares to the Booley Family Trust on the same day.

Following these transactions Mr Booley has a beneficial interest in 4,610,723 Shares representing approximately 1.91% of the issued share capital of the Company.

For further information:

Notes to editors:

About Alliance

Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and, following the Cambridge Laboratories acquisition, owns or licenses the rights to more than 50 pharmaceutical products and continues to explore opportunities to expand the range.

Alliance's products are prescribed in the treatment of a wide range of conditions and include products used in the treatment of dermatological conditions, in oncology, in childbirth, in the prevention of heart disease, in Parkinson's disease, in nutrition and in nasal infections. Alliance's sales are mainly prescription driven. Its products are distributed to hospitals directly and to pharmaceutical wholesalers, which service both hospital and retail pharmacies with their prescription requirements.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.